Insulin degludec/liraglutide

Drug Profile

Insulin degludec/liraglutide

Alternative Names: GLP-1 and basal insulin combination; IDegLira; Insulin degludec/Victoza; Liraglutide/insulin degludec; Liraglutide/NN 1250; Liraglutide/Tresiba; NN 1250/liraglutide; NN-9068; Tresiba/liraglutide; Victoza/insulin degludec; Xultophy

Latest Information Update: 27 Jun 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Novo Nordisk
  • Class Antihyperglycaemics; Glucagon-like peptides; Insulins; Pancreatic hormones
  • Mechanism of Action Glucagon like peptide 1 receptor agonists; Glucagon receptor antagonists; Ornithine decarboxylase stimulants; Phosphokinase stimulants; Protein tyrosine kinase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Type 2 diabetes mellitus

Most Recent Events

  • 10 Jun 2017 New efficacy and adverse events data from the phase IIIb DUAL VII trial in Type-2 diabetes mellitus presented at the 77th Annual Scientific Sessions of the American Diabetes Association (ADA-2017)
  • 25 May 2017 Novo Nordisk initiates enrolment in the phase III DUAL™ II China trial for Type-2 diabetes mellitus (Adjunctive treatment, Treatment-experienced, In adults, In the elderly) in China (SC) (NCT03175120)
  • 25 May 2017 Phase-III clinical trials in Type-2 diabetes mellitus (Adjunctive treatment, In adults, In the elderly) in China (SC) (NCT03172494)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top